Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies banner

As the next generation of multispecific therapies, antibody-drug conjugates, and combination therapies continues to develop, there is a growing focus on ensuring the safety and efficacy of these therapies. Safety and toxicity pose unique challenges among different therapeutic modalities. At Cambridge Healthtech Institute's 2nd annual Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies conference, sessions will build upon past and present research to explore the field is addressing these challenges. The conference will compare and contrast different therapeutic modalities, and speakers from industry, academia, and the clinic will go over strategies for mitigating toxicity, managing combination therapies, reducing side effects, and closing disparities in access. This meeting will complement topics in multispecific antibody discovery and engineering for meeting unmet clinical needs

Recommended Short Course*
Monday, 4 November, 14:00 – 17:00
SC1: Developability of Bispecific Antibodies: Formats and Applications
*Separate registration required. See short courses page for details. All short courses take place in-person only.






For more details on the conference, please contact:

Iris Goldman
Conference Producer
Cambridge Healthtech Institute
Phone: (+1) (781) 247-1814
Email: igoldman@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com